| scholarly article | Q13442814 |
| P50 | author | Victor C. Kok | Q48273012 |
| P2093 | author name string | Victor C Kok | |
| P2860 | cites work | In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B | Q28202233 |
| Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial | Q28534786 | ||
| Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial | Q33340785 | ||
| Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. | Q33858197 | ||
| Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines. | Q34062522 | ||
| Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer | Q34964991 | ||
| Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp. | Q34989416 | ||
| Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer? | Q35608666 | ||
| A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer | Q35678690 | ||
| Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane | Q35721526 | ||
| Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer | Q37356090 | ||
| Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development | Q37566220 | ||
| Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer | Q37698199 | ||
| Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine | Q37777290 | ||
| Advances in therapy: eribulin improves survival for metastatic breast cancer | Q37788507 | ||
| Eribulin mesylate | Q37920974 | ||
| A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer | Q37944440 | ||
| Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells | Q38924096 | ||
| Retinal metastasis regression with eribulin in a heavily pretreated breast cancer patient | Q38978443 | ||
| Anti-Cancer Products from Marine Sponges: Progress and Promise | Q39001534 | ||
| A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden | Q41669687 | ||
| Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579). | Q41719274 | ||
| Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer | Q42653377 | ||
| Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment | Q42715686 | ||
| Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane | Q46059531 | ||
| A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors. | Q51301390 | ||
| Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. | Q52846107 | ||
| Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9. | Q54262056 | ||
| Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. | Q55073162 | ||
| Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an | Q57578399 | ||
| A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC | Q71455446 | ||
| Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy | Q72528110 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 109-115 | |
| P577 | publication date | 2015-12-15 | |
| P1433 | published in | Breast Cancer : Basic and Clinical Research | Q27722056 |
| P1476 | title | Eribulin in the Management of Advanced Breast Cancer: Implications of Current Research Findings | |
| P478 | volume | 9 |
| Q50045537 | Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY). |
| Q47111016 | Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study |
| Q47893785 | Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer. |
Search more.